Comment

Comment by Dr. Krishna Kumari Challa 39 minutes ago

3I/ATLAS: Interstellar object 'may be oldest comet ever seen'

A mystery interstellar object discovered last week is likely to be the oldest comet ever seen—possibly predating our solar system by more than 3 billion years, researchers say.

The "water ice-rich" visitor, named 3I/ATLAS, is only the third known object from beyond our solar system ever spotted in our cosmic neighborhood and the first to reach us from a completely different region of our Milky Way galaxy.

It could be more than 7 billion years old.

Unlike the previous two objects to enter our solar system from elsewhere in the cosmos, 3I/ATLAS appears to be traveling on a steep path through the galaxy, with a trajectory that suggests it originated from the Milky Way's "thick disk"—a population of ancient stars orbiting above and below the thin plane where the sun and most stars reside.

All non-interstellar comets such as Halley's comet formed with our solar system, so are up to 4.5 billion years old.

But interstellar visitors have the potential to be far older, and of those known about so far our statistical method suggests that 3I/ATLAS is very likely to be the oldest comet we have ever seen.

The object was first spotted on 1 July 2025 by the ATLAS survey telescope in Chile, when it was about 670 million km from the sun.

Research predicts that, because 3I/ATLAS likely formed around an old, thick-disk star, it should be rich in water ice.

This is an object from a part of the galaxy we've never seen up close before. Researchers think there's a two-thirds chance this comet is older than the solar system, and that it's been drifting through interstellar space ever since.

As it approaches the sun, sunlight will heat 3I/ATLAS's surface and trigger cometary activity, or the outgassing of vapor and dust that creates a glowing coma and tail.

Early observations already suggest the comet is active, and possibly larger than either of its interstellar predecessors, 1I/'Oumuamua (spotted in 2017) and 2I/Borisov (2019).

The Galactic Interstellar Object Population in the LSST. conference.astro.dur.ac.uk/eve … 7/contributions/751/

Matthew J. Hopkins et al, From a Different Star: 3I/ATLAS in the context of the Ōtautahi-Oxford interstellar object population model, arXiv (2025). DOI: 10.48550/arxiv.2507.05318 ,
doi.org/10.48550/arXiv.2507.05318

Comment by Dr. Krishna Kumari Challa 17 hours ago

Bacteria takes the poison out of mercury
An engineered strain of the gut microbe Bacteroides thetaiotaomicron can break down methylmercury (MeHg), a potent neurotoxin that’s increasingly found in seafood as a result of pollution. Researchers inserted two genes into the bacteria that snip MeHg into a carbon molecule and plain mercury, which isn’t as easily absorbed by the body. Pregnant mice that were given the engineered B. thetaiotaomicron and fed a diet high in MeHg-laced tuna excreted more mercury in their faeces and had lower levels of mercury in both maternal and foetal tissues than those with a normal microbiome.

https://www.cell.com/cell-host-microbe/abstract/S1931-3128(25)00142-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1931312825001428%3Fshowall%3Dtrue

Comment by Dr. Krishna Kumari Challa 18 hours ago

Newly discovered molecule may explain reduced muscle mass in type 2 diabetes

Researchers  have discovered a previously unknown molecule that may explain why people with type 2 diabetes often suffer from muscle weakness and muscle loss—a condition that has a major impact on quality of life and overall health.

In the new study, published in Science Advances, researchers have identified a previously unknown molecule, TMEM9B-AS1, which may explain why people with type 2 diabetes often suffer from muscle weakness and loss of muscle mass. The molecule is a long non-coding RNA that plays an important role in regulating cellular functions.

The researchers discovered that TMEM9B-AS1 is significantly reduced in skeletal muscles in individuals with type 2 diabetes, and its absence disrupts the machinery needed to build new muscle proteins.

The study shows that TMEM9B-AS1 supports the stability of MYC, a key gene that drives the production of ribosomes—the factories that manufacture proteins. Without this RNA molecule, MYC becomes unstable, and muscle cells lose their ability to maintain normal protein production. This may help explain the muscle deterioration we often see in people with metabolic diseases.  

Ilke Sen et al, Down-regulation of human-specific lncRNA TMEM9B-AS1 in skeletal muscle of people with type 2 diabetes affects ribosomal biogenesis, Science Advances (2025). DOI: 10.1126/sciadv.ads4371

Comment by Dr. Krishna Kumari Challa 21 hours ago

Global vaccine stockpiles prevented more than 5.8 million cases

The life-saving impact of global vaccine stockpiles to address outbreaks of vaccine-preventable diseases has been demonstrated in new Burnet Institute research.

Published in the journal BMJ Global Health, the study considered 210 outbreaks that occurred between 2000 and 2023 for five diseases—cholera, Ebola, measles, meningitis and yellow fever.

Outbreak response immunization was estimated to have prevented more than 5.8 million cases and 327,000 deaths across these outbreaks, providing economic benefits of almost US$32 billion.

For diseases with routine vaccination programs, maintaining high levels of population immunity is vital for preventing large outbreaks.

But when outbreaks do occur, a rapid vaccine response typically provides the greatest protective impact for the population at risk—and the faster the response, the greater the impact. While vaccines are amazing preventively, they are also excellent when used reactively to control outbreaks and save lives.

Vaccine stockpiles have not only prevented many cases and deaths, but they have also prevented outbreaks from reaching the point where they cause substantive issues, and that's really important, say the researchers.

 Dominic Delport et al, Estimating the historical impact of outbreak response immunisation programmes across 210 outbreaks in low and middle-income countries, BMJ Global Health (2025). DOI: 10.1136/bmjgh-2024-016887. gh.bmj.com/content/10/7/e016887

Comment by Dr. Krishna Kumari Challa 21 hours ago

Based on the data gathered during the study period, HPV16/18 has been almost eliminated among vaccinated women in Denmark. The prevalence of these two types in the samples decreased to < 1% in 2021 from 15–17% before the vaccination of girls. In addition, the prevalence of types 16/18 in women who had not been vaccinated against HPV remained at 5%, which, according to the authors, "strongly indicates population immunity."

Despite the evidence of protection through vaccination, about one-third of women screened during the study period still had HPV infection with high-risk HPV types not covered by the offered vaccines—and new infections with these types were more frequent in vaccinated women than in unvaccinated women.
There was a low prevalence of HPV16/18 during the seven-year study period and women who have been vaccinated against HPV as girls are expected to have a considerably lower risk of cervical cancer compared with previous generations.

Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study, Eurosurveillance (2025). DOI: 10.2807/1560-7917.ES.2025.30.27.2400820

Part 2

Comment by Dr. Krishna Kumari Challa 21 hours ago

Vaccines work: Data show real-world evidence of stable protection against HPV-related cervical cancer

Among the more than 100 types of human papillomavirus (HPV), at least 14 are considered as "high-risk" types which can cause (cervical) cancer. After breast cancer, cervical cancer is the most common cancer  among women aged 15–44 years.

Before HPV vaccination among teenage girls started in Denmark, high-risk HPV was found in all cervical cancers. HPV types 16/18 accounted for around three quarters (74%) of cervical cancers. These two types are covered in the 4-valent HPV vaccine offered to girls since 2008 as well as the 9-valent vaccine, which has been in use in Denmark since November 2017.
One third (26%) of cervical cancers prior to the HPV immunization campaign were caused by high-risk types that are not covered by the 2- and 4-valent vaccine.

In their research article published in Eurosurveillance, a team led by Mette Hartmann Nonboe examined the HPV status of cervical samples over time among women (22–30 years) at the screening age for cervical cancer who were vaccinated as girls.

They tested up to three consecutive cervical cell samples per participant provided by the contributing pathology departments in Denmark for HPV.

In total, 17,252 women with at least one cervical cell sample were registered between 1 February 2017 and 29 February 2024. During the seven years of the randomized "Trial23" study (cervical cancer screening starts at age 23 in Denmark), 84% of women in the study had at least one cell sample taken. The authors compared HPV prevalence, persistence and incidence among vaccinated and unvaccinated women.
Part 1

Comment by Dr. Krishna Kumari Challa 22 hours ago

Genomic study reveals deep roots of human survival and adaptation in Himalayas

A new genomic study reveals how human populations adapted, survived, and diversified in the Himalayas, one of the most extreme and challenging environments on Earth.

Researchers analyzed whole-genome sequences from diverse Himalayan ethnic groups, many of which had never been genetically studied before at this level.

Published in Current Biology, the study shows that population structure in the Himalayas began over 10,000 years ago, thousands of years before archaeological evidence of permanent settlement at high altitudes. This early divergence challenges long-standing assumptions about when and how diverse groups first began accessing the extreme elevations of the Himalayas.

 This study offers an unprecedented window into the genetic legacy of Himalayan populations and their extraordinary adaptations to high-altitude life. It reveals how migration, isolation, and natural selection came together to shape human survival in one of the world's most challenging environments.

The study identifies novel genetic variants linked to adaptation in hypoxia, metabolism, immunity, and physical activity. It also confirms that the Denisovan EPAS1-derived gene, known to be crucial for surviving low-oxygen conditions, is widespread across all high-altitude Himalayan groups.

The gene variants originate from the extinct archaic human species known as Denisovan. Strikingly, other variants were also found in some lowland populations, including those previously reported in Southeast Asian groups known for their exceptional breath-hold diving abilities, pointing to unexpected evolutionary links.

Whole-genome sequences provide insights into the formation and adaptation of human populations in the Himalayas, Current Biology (2025). DOI: 10.1016/j.cub.2025.06.048. www.cell.com/current-biology/f … 0960-9822(25)00808-5

Comment by Dr. Krishna Kumari Challa yesterday

Using advanced techniques to manipulate the activity of specific brain cells, the researchers discovered a new spinothalamic pathway in mice. In this circuit, pain signals are sent from the spinal cord into a different part of the thalamus, which has connections to the amygdala, the brain's emotional processing center. This particular group of neurons in the thalamus can be identified by their expression of CGRP (calcitonin gene-related peptide), a neuropeptide.
When the researchers "turned off" (genetically silenced) these CGRP neurons, the mice still reacted to mild pain stimuli, such as heat or pressure, indicating their sensory processing was intact. However, they didn't seem to associate lasting negative feelings with these situations, failing to show any learned fear or avoidance behaviors in future trials. On the other hand, when these same neurons were "turned on" (optogenetically activated), the mice showed clear signs of distress and learned to avoid that area, even when no pain stimuli had been used.

Pain processing is not just about nerves detecting pain; it's about the brain deciding how much that pain matters.
Understanding the biology behind these two distinct processes will help us find treatments for the kinds of pain that don't respond to traditional drugs.
Many chronic pain conditions—such as fibromyalgia and migraine—involve long, intense, unpleasant experiences of pain, often without a clear physical source or injury. Some patients also report extreme sensitivity to ordinary stimuli like light, sound, or touch, which others would not perceive as painful.
Overactivation of the CGRP spinothalamic pathway may contribute to these conditions by making the brain misinterpret or overreact to sensory inputs. In fact, transcriptomic analysis of the CGRP neurons showed that they express many of the genes associated with migraine and other pain disorders.
Notably, several CGRP blockers are already being used to treat migraines. This study may help explain why these medications work and could inspire new nonaddictive treatments for affective pain disorders.

 Sukjae J. Kang et al, Thalamic CGRP neurons define a spinothalamic pathway for affective pain, Proceedings of the National Academy of Sciences (2025). DOI: 10.1073/pnas.2505889122

Part 2

Comment by Dr. Krishna Kumari Challa yesterday

From injury to agony: Scientists discover brain pathway that turns pain into suffering

Pain isn't just a physical sensation—it also carries emotional weight. That distress, anguish, and anxiety can turn a fleeting injury into long-term suffering.

Researchers  have now identified a brain circuit that gives physical pain its emotional tone, revealing a new potential target for treating chronic and affective pain conditions such as fibromyalgia, migraine, and post-traumatic stress disorder (PTSD).

Published in Proceedings of the National Academy of Sciences, the study identifies a group of neurons in a central brain area called the thalamus that appears to mediate the emotional (affective) side of pain in mice. This new pathway challenges the textbook understanding of how pain is processed in the brain and body.

For decades, the prevailing view was that the brain processes sensory and emotional aspects of pain through separate pathways. This study provides strong evidence that a branch of the sensory pain pathway directly mediates the affective experience of pain.

The physical sensation of pain is what allows you to immediately detect it, assess its intensity, and identify its source. The affective part of pain is what makes it so unpleasant. This emotional discomfort motivates you to take action and helps you learn to associate negative feelings with the situation so you can avoid it in the future.

This is a critical distinction. Most people start to perceive pain at the same stimulus intensities, meaning we all process the sensory side of pain fairly similarly. In comparison, our ability to tolerate pain varies greatly. How much we suffer or feel threatened by pain is determined by our affective processing, and if it becomes too sensitive or lasts too long, it can result in a pain disorder. This makes it important to understand which parts of the brain control these different dimensions of pain.
Sensory pain was thought to be mediated by the spinothalamic tract, a pathway that sends pain signals from the spinal cord to the thalamus, which then relays them to sensory processing areas across the brain.

Affective pain had generally been thought to be mediated by a second pathway called the spinoparabrachial tract, which sends pain information from the spinal cord into the brainstem.
Part 1

Comment by Dr. Krishna Kumari Challa yesterday

Scientists use AI to create protein that kills E. coli

In the last year, there has been a surge in proteins developed by AI that will eventually be used in the treatment of everything from snakebites to cancer. What would normally take decades for a scientist to create—a custom-made protein for a particular disease—can now be done in seconds.

For the first time,  scientists have used Artificial Intelligence (AI) to generate a ready-to-use biological protein, in this case, one that can kill antibiotic-resistant bacteria like E. coli.

This study, published in Nature Communications, provides a new way to combat the growing crisis caused by antibiotic-resistant superbugs.

These proteins are now being developed as pharmaceuticals, vaccines, nanomaterials and tiny sensors, with many other applications yet to be tested.

Inhibiting heme piracy by pathogenic Escherichia coli using de novo-1 designed proteins, Nature Communications (2025). DOI: 10.1038/s41467-025-60612-9 On BioRxiv. DOI: 10.1101/2024.12.05.626953

• ‹ Previous
• 1
• 2
• 3
• …
• 1083
• Next ›
• Page